Category - Feature

Feature

Fabian Gerlinghaus talks up the power of the Cellares Cell Shuttle

As a co-founder and CEO of closely-held Cellares, which is pioneering an automated approach to cell therapy manufacturing, Fabian Gerlinghaus, an aerospace engineer by training, made the switch to biotech eight years...

November 30, 2021

Feature

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Genocea Biosciences (NASDAQ:GNCA) is on a mission to make better cancer immunotherapies for patients, beginning with better target discovery.

November 23, 2021

Feature

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...

November 9, 2021

Feature

NervGen unleashing nervous system to heal itself

NervGen Pharma (TSX-V:NGEN; OTCQX:NGENF) is developing a new class of drugs that repairs damage to the nervous system and restores motor, sensory and cognitive function to diseases where there are currently no approved...

November 2, 2021

Feature

Lanier Biotherapeutics to develop first-in-class biologics portfolio for specialty diseases

Recently launched Lanier Biotherapeutics is developing specialty biologic treatments for indications in multifunctional retina, dermatology and Type 2 inflammation diseases.

October 26, 2021

Feature

Aligos Therapeutics targeting functionally curative HBV regimen

Even though a number of antiviral medications are in use to treat chronic hepatitis B virus (HBV) infections, Aligos Therapeutics (NASDAQ:ALGS) is going one step further with a portfolio of drug candidates in clinical...

October 19, 2021

Feature

Acasti Pharma transitions to orphan diseases from cardiovascular

After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...

October 12, 2021

Feature

ContraFect advancing new modality for antibiotic-resistant infections

In a bid to counter the next great health crisis, ContraFect (NASDAQ:CFRX) is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs).

October 5, 2021

Feature

Aptevo Therapeutics oncology pipeline offers multiple shots on goal

Aptevo Therapeutics (NASDAQ:APVO) has developed a broad portfolio of potential immuno-oncology therapies with multiple mechanisms of action from two differentiated bispecific and multi-specific antibody platform...

September 28, 2021

Feature

ReShape Lifesciences forging weight loss and metabolic health solutions

With an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease, ReShape Lifesciences (NASDAQ:RSLS) is reshaping patients minds, bodies and lives.

September 21, 2021

Category - Feature

Fabian Gerlinghaus talks up the power of the Cellares Cell Shuttle

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

NervGen unleashing nervous system to heal itself

Lanier Biotherapeutics to develop first-in-class biologics portfolio for specialty diseases

Aligos Therapeutics targeting functionally curative HBV regimen

Acasti Pharma transitions to orphan diseases from cardiovascular

ContraFect advancing new modality for antibiotic-resistant infections

Aptevo Therapeutics oncology pipeline offers multiple shots on goal

ReShape Lifesciences forging weight loss and metabolic health solutions

General

More